NxStage Names New Chief Financial Officer and Appoints Leader of NxStage Centers of Excellence

   NxStage Names New Chief Financial Officer and Appoints Leader of NxStage
                            Centers of Excellence

PR Newswire

LAWRENCE, Mass., June 26, 2013

LAWRENCE, Mass., June 26, 2013 /PRNewswire/ --NxStage Medical, Inc. (Nasdaq:
NXTM), a leading manufacturer of innovative dialysis products, today announced
that Matthew W. Towse has been appointed Senior Vice President and Chief
Financial Officer, and Robert S. Brown, former Senior Vice President and Chief
Financial Officer, has been named President of NxStage Kidney Care, Inc., the
subsidiary responsible for NxStage's Centers of Excellence initiative. In
addition, Kevin Hershberger, NxStage's Controller and Vice President of
Finance, has been appointed, to the newly established post of Vice President,
Chief Accounting Officer and Controller.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

"Matt is a seasoned financial executive with extensive experience aligning the
financial and business strategies of high-growth companies. As our new CFO,
Matt's leadership will be important as we execute against our strategic growth
initiatives," stated Jeffrey H. Burbank, Founder and Chief Executive Officer
of NxStage. "This is a positive move that expands and strengthens our
management team."

Mr. Towse has over 25 years of experience in global financial management with
both public and private companies across multiple industries. He served as
Vice President and Chief Financial Officer of Vette Corp., a venture-capital
backed global design, engineering and manufacturing technology company from
2006 until its acquisition by a strategic buyer in 2012. From 2003 to 2005, he
served as Senior Vice President and Chief Financial Officer of Fairchild
Semiconductor International, Inc. Previously, Mr. Towse served as Fairchild's
Vice President and Corporate Treasurer from 1997 to 2003, and held various
financial management positions with National Semiconductor from 1991 to 1997
before becoming part of the team that spun-out Fairchild from National.
Earlier in his career, Mr. Towse was an audit manager with Ernst & Young and
most recently, he served as an Interim CFO with Tatum, LLC.

Mr. Towse is a Certified Public Accountant and received a B.B.A. from the
University of Notre Dame.

Burbank continued, "Over the past six years, Robert has built a world-class
finance team that has supported both significant revenue growth and cost
improvements. He has been instrumental in helping to lead the organization
with strong financial and operational management. We expect to leverage his
strengths into our Centers of Excellence efforts."

Kevin Hershberger has been serving as NxStage's Controller and Vice President
of Finance since 2008. Throughout his tenure at NxStage he has been
responsible for the Company's financial and internal control activities,
including accounting, financial planning, reporting, budgeting and
forecasting.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq:NXTM) is a medical device company, headquartered
in Lawrence, Massachusetts, USA, that develops, manufactures and markets
innovative systems for the treatment of end-stage renal disease, or ESRD, and
acute kidney failure. NxStage is leading the development of the home
hemodialysis market in the US with the only portable hemodialysis machine, the
System One, cleared for home use by the FDA. For more information on NxStage
and its products, please visit the company's website at
http://www.nxstage.com/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements contained in
this release that are not clearly historical in nature are forward-looking,
and the words "anticipate," "believe," "expect," "estimate," "plan," and
similar expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors including
those that are discussed in NxStage's filings with the Securities and Exchange
Commission, including the Quarterly Report on Form 10-Q for the quarter ended
March 31, 2013. NxStage is under no obligation to (and expressly disclaims any
such obligation to) update or alter its forward-looking statements, whether as
a result of new information, future events or otherwise.

SOURCE NxStage Medical, Inc.

Website: http://www.nxstage.com
Contact: Kristen Sheppard, +1-978-332-5923, ksheppard@nxstage.com
 
Press spacebar to pause and continue. Press esc to stop.